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We previously performed a global analysis of the gene expression of gastric cancer cell lines established from metastases to the
peritoneal cavity with the cDNA microarray method, which made it possible to analyse the expression of approximately 21168
genes for the identification of novel markers for the detection of micrometastases in the peritoneal cavity. One of the upregulated
genes is dopa decarboxylase (DDC), which is responsible for the synthesis of the key neurotransmitters dopamine and serotonine.
We have examined its potential as a novel marker for the detection of peritoneal micrometastases of gastric cancer.
DDC mRNA in the peritoneal wash from 112 gastric cancer patients was quantified for comparison of carcinoembryonic antigen
(CEA) mRNA by means of real-time reverse transcriptase–polymerase chain reaction (RT–PCR) with a fluorescently labelled probe
to predict peritoneal recurrence. The quantity of DDC and CEA correlated with wall penetration. Real-time RT–PCR could
quantitate 10–10
6 DDC-expressing gastric cancer cells per 10
7 mesothelial cells. The cutoff value was set at the upper limit of the
quantitative value for noncancer patients, and those above this cutoff value constituted the micrometastasis (MMþ) group. Of 15
cases with peritoneal dissemination, 13 were MMþDDC (87% sensitivity), and one of 48 t1 cases was MMþ (98% specificity).
DDC levels in peritoneal washes from patients with synchronous peritoneal metastases were more than 50 times higher than in
those from patients without metastasis (Po0.01). For 15 cases of peritoneal dissemination (seven cases were cytologically positive),
DDC was positive in 13 cases (87% sensitivity), but CEA failed to detect micrometastases in four cases (73% sensitivity), indicating
that DDC is in some cases superior to CEA for the detection of peritoneal micrometastases of gastric cancer in terms of sensitivity as
well as specificity, especially for poorly differentiated adenocarcinomas. A combination of CEA and DDC improved the accuracy of
diagnosis up to 94%.
These results suggest that DDC is potentially a novel marker for peritoneal dissemination of gastric cancer and that quantitative RT–
PCR of DDC is reliable and efficient for the selection of patients for adjuvant intraperitoneal chemotherapy to prevent peritoneal
recurrence.
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The prognosis for gastric cancer that has invaded as far as the
gastric serosa is still poor, with a 5-year survival of less than 35%
(Yamazaki et al, 1989). Peritoneal dissemination is reported to be
the most frequent type of recurrence after curative resection in
such gastric cancer cases (Baba et al, 1989; Kodera et al, 1996).
Free cancer cells derived from serosal invasion may thus be an
indicator of early peritoneal seeding with subsequent formation of
metastatic colonies, so that their detection is likely to be a useful
tool for predicting the outcome for patients with advanced gastric
cancers (Abe et al, 1995; Bonenkamp et al, 1996). Conventional
intraperitoneal cytology (CY) has recently become a common
procedure for the detection of free gastric cancer cells in the
peritoneal cavity. Cytology-positive cases are classified as Stage IV
of the UICC gastric cancer classification and curative operation is
impossible in such cases. Depending on the cytological results,
operative procedures including lymphnode dissection may have to
be changed, and intensive chemotherapy may have to be used for
such cases. Conventional CY, however, lacks sensitivity and some
patients with negative CY results have nevertheless been found to
show recurrence in the form of peritoneal dissemination.
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antigen (CEA)-specific RT–PCR to detect free cancer cells in the
peritoneal fluids (Nakanishi et al, 1997); CEA is not perfect as a
marker, so that identification of more reliable markers is needed.
We previously performed a global analysis of the differential
gene expression of a gastric cancer cell line established from a
primary main tumour and of other cell lines established from
metastases to the peritoneal cavity (Sakakura et al, 2002). The
application of a high-density cDNA microarray method made it
possible to analyse the expression of approximately 21168 genes.
Our investigations showed that 24 genes were upregulated and 17
genes downregulated, in addition to the expression sequence tags
(ESTs) in gastric cancer cell lines established from metastases to
the peritoneal cavity. One of these upregulated genes is dopa
decarboxylase (DDC).
DDC is an enzyme that metabolises DOPA (3,4-dihydroxyphe-
nylalanine) to DA (dopamine), and increased urine excretion of
catecholamine metabolites is well known as a key diagnostic
feature of neuroblastoma (Eldrup et al, 2001). DDC is responsible
for the synthesis of the key neurotransmitters dopamine and
serotonin, and is frequently expressed in neuroblastoma and
small-cell carcinoma of the lung (Jensen et al, 1990; Gilbert et al,
1999). DOPA is used as a tumour marker for children with
neuroblastoma (Ikeda et al, 1996), but the role of DDC in gastric
cancer peritoneal dissemination is still unclear.
In the study presented here, even more sensitive detection of
micrometastases of cancer cells could be achieved through
amplification of the novel marker DDC by means of quantitative
reverse transcriptase–polymerase chain reaction (RT–PCR) for
peritoneal lavage fluid cells. This detection method can be
expected to result in a more accurate prediction of peritoneal
recurrence in gastric cancer patients.
MATERIALS AND METHODS
Cell culture, peritoneal washes and RNA preparation
Gastric cancer cell lines SNU-1, SNU-5, SNU-16, SNU-620 cells
were established previously by Park et al. KATO-III, GT3TKB,
MKN7 and acute myeloid leukaemia cell line HL60 were purchased
from the Riken Cell Bank (Tsukuba, Japan), and NUGC-3 cells
from the Health Science Research Resources Bank (Osaka, Japan).
GT3TKB cells were maintained at 371C in a humidified atmosphere
of 5% CO2 in high-glucose DMEM (Sigma, St Louis, MO, USA),
whereas MKN7 and NUGC-3 were maintained in RPMI 1640
(Sigma). Both media were supplemented with 10% foetal bovine
serum, penicillin and streptomycin. When they had reached 80–
90% confluence, cells were washed with ice-cold PBS and
homogenised immediately in Isogen reagent (Nippon Gene, Osaka,
Japan), and total RNA was extracted. mRNA was extracted from
each cell line with the FAST track kit Ver.2 (Invitrogen), according
to the manufacturer’s instructions. Mesothelial cell line Met5A was
established by Reddel et al. (Duncan et al, 1993; Nakabayashi et al,
1999).
The study population consisted of 112 patients with gastric
cancer and 15 patients with benign diseases, including cholecys-
tolithiasis and leiomyoma of the stomach, who underwent
surgery at Kyoto Prefectural University of Medicine between
1999 and 2003. Ascitic fluid was collected from the Douglas cavity
during laparotomy. Written informed consent was obtained from
each patient prior to tissue acquisition. In the absence of
ascites, 150ml of saline was introduced into the Douglas cavity
at the beginning of the operation and aspirated after gentle
stirring. These washes were centrifuged at 2000rpm for 10min
to collect intact cells, which were rinsed with PBS, dissolved
in ISOGEN RNA extraction buffer (Nippon Gene, Tokyo) and
stored at  801C until use. Samples were centrifuged at 12000rpm
in a rotor (RA-48J, Kubota Fujioka, Japan) at 41C for ethanol
precipitation.
Northern blot analysis
Northern blot was performed as previously described by us
(Sakakura et al, 1994, 1996). In brief, the total cellular RNA was
prepared with the guanidine isothiocyanate–phenol–chloroform
procedure. Poly(A)
þ RNA was selected with an oligo dT column
(Cat. No. R500-50, Invitrogen), and then fractionated on 1%
agarose/2.2 M formaldehyde gels. Probes were labelled with
32Pb y
random priming. Each blot was then hybridised with the probe for
the selected gene and b-actin. Signals were analysed with a BAS
2000 image analyser followed by calculation of the degree of
overexpression compared to the control.
Real-time quantitative RT–PCR
cDNA was produced from total RNA by using a Superscript
Preamplification System (BRL, Bethesda, MD, USA) in accordance
with the procedures suggested by the manufacturer. Total RNA
(2mg) was heated to 701C for 10min in 14ml of duethylpyrocarbo-
nate-treated water containing 0.5mg oligo (dT). Synthesis buffer
(10 , 500mM Tris-HCl, pH 8.3, 750mM KCl, 30mM MgCl2), 2ml
10mM dNTP mix, 2ml 0.1 M DTT, and reverse transcriptase
(Superscript RT; 200UmL
 1, GIBCO BRL, Gaithersburg, MD,
USA) were added to the sample. The resulting reaction mixture
was incubated at 421C for 50min, and the reaction was terminated
by incubating the mixture at 901C for 5min.
Quantitative PCR was performed using the real-time’Taqman
TM’ technology as described by Nakanishi et al (2000) and the
results were analysed on a Model 5700 Sequence Detector (Applied
Biosystems Corp., Foster City, CA, USA).
The DDC RT–PCR primers were 50-AAGCACAGCCATCAG-
GATTCA-30 and 50-TGGACATGCTTGCGGATATAAG-30, and the
CEA RT–PCR primers were 50-TCTGGAACTTCTCCTGGTCTCT-
CAGCTGG-30 and 50-TGAAGCTGTTGCAAATGCTTTAAGGAA-
GAAGC-30. Hybridisation probes, which bind to PCR products,
were labelled with a reporter dye, FAM, on the 50 nucleotide and a
quenching dye, TAMRA, on the 30nucleotide. The sequences of
hybridisation probes were CEA: 50-(FAM) CATCTG-
GAACTTCTCCTGGTCTCTCAGC (TAMRA)-30 and DDC: 50-
(FAM) AAGCACAGCCATCAGGATTCA (TAMRA)-30.
In total, 50ml reactions contained: 1.25U Amp-Taq DNA
polymerase, 1  PCR reaction buffer, 180ng of each primer,
200mM dNTP, 400mM dUTP, 100nM Taqman probe and 0.5U
Amplirase (Applied Biosystems Corp.). The Ct value correspond-
ing to the number of cycles at which the fluorescence emission
monitored in real time reached a threshold of 10 standard
deviations (s.d.) above the mean base line emission from cycles
1 to 40 was measured in serial dilutions of control cDNA, and
analysed for each target. CEA and DDC served as standard curves
from which the rates of change in Ct values were determined. The
cycling parameters were 2min at 501C and 10min at 951C,
followed by 40 cycles of 15s at 951C and 1min at 601C.
To minimise the errors arising from the validation of the initial
amount of RNA in the samples, b-actin mRNA was amplified as an
internal reference against which other RNA values could be
normalised. The primers and the probe for the b-actin RNA were
purchased from Applied Biosystems. Normalised results were
expressed as the ratio of copies of each of the genes to copies of the
b-actin gene.
Statistical methods for analysis
Statistical analysis was performed using the NAP system
programmed by Aoki (Version 4.0). The first objective of the
statistical analysis was to examine the influence of DDC expression
DDC for gastric cancer peritoneal micrometastasis
C Sakakura et al
666
British Journal of Cancer (2004) 90(3), 665–671 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yon clinicopathological factors with the unpaired T-test. The
various groups of patients were compared by means of either w
2
test or Mann–Whitney U-test. The results with P-values of less
than 0.05 were considered statistically significant.
RESULTS
LightCycler validation of rapid quantitative RT–PCR
Real-time fluorescence PCR monitoring with the LightCycler using
hybridisation probes allowed for rapid and sensitive detection of
DDC mRNA from the patient samples. With this method, 10–10
6
DDC-expressing gastric cancer SNU-16 cells per 10
7 mesothelial
cells could be quantitated. No significant level of DDC mRNA was
detected in peripheral blood lymphocytes or mesothelial cells from
healthy volunteers.
Quantification of messages with the LightCycler was assessed by
determination of the crossover point (Ct), the cycle when
fluorescence of a given sample rose above the background level
to yield the maximal slope with respect to log-linear amplification.
Figure 1B illustrates a standard curve constructed by plotting the
log number of 10-fold serially diluted SNU-16 cells against their
respective Cts. DDC mRNA values for patient samples with
unknown concentration were calculated with reference to the
calibration curve.
Expression of DDC mRNA in gastric cancer cell lines,
mesothelial cell line, normal gastric mucosa and cancerous
tissues
Northern blot analysis showed a high expression level of DDC
only in cells with a high potential for peritoneal dissemination
and a low expression level in all the cells with a low potential.
The mesothelial cell line Met5A and human leukaemia cell line HL-
60 showed a very low level of DDC expression (Figure 2A).
The DDC expression was detected in both normal gastric
mucosa and gastric cancer tissues of clinical specimens, but
the DDC expression was higher in the latter than in the former.
It was significant in poorly differentiated adenocarcinomas, but
the difference was not significant between cancerous tissue and
normal mucosa in cases of well-differentiated adenocarcinoma.
The DDC expression was significantly higher than in mesothelial
cells from peritoneal wash, especially in the case of poorly
differentiated adenocarcinoma (Figure 2B). The summary of
DDC mRNA and clinicopathological factors in gastric cancer
patients is shown in Table 1. DDC expression correlates with
differentiation, depth of invasion, lymphatic invasion and
peritoneal dissemination.
DDC mRNA/b-actin mRNA ratio and the degree of wall
invasiveness
In order to standardise the amount of RNA in each sample, b-actin
mRNA was used as an internal control. The value for extracted
DDC was determined as the DDC mRNA/b-actin mRNA ratio.
The average DDC mRNA/b-actin mRNA ratio ( 10
7)b yt
classification was: t1, 39þ13; t2, 162þ93; t3, 39210þ6613; t4,
17300þ4139 (averageþs.d.). Subjects were further classified into
positive cases (t3, t4) and negative (t1, t2) for invasion of the
serosa. The results showed that the DDC mRNA/b-actin mRNA
A
B
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Figure 1 Representative results of real-time RT–PCR with LightCycler
and calibration curve for DDC mRNA estimation. (A) Run profile vs PCR
cycles. Six external standards (lines 1–6) were compared with two patient
samples (lines 10 and 11) with unknown concentrations, which were
amplified with real-time ‘Taqman TM’ technology and analysed with a
Model 5700 Sequence Detector: line 1¼1; line 2¼10; line 3¼10
2; line
4¼10
3; line 5¼10
4; line 6¼10
5; line 7¼10
6 SNU-16 gastric cancer cell
equivalent cDNA, line 8¼Met 5A; line 9¼HL60; line 10¼peritoneal
wash with negative conventional RT–PCR results; lines 11 and
12¼peritoneal wash with positive conventional RT–PCR results. (B)
Calibration curve for DDC mRNA estimation constructed from data for
external controls (A) by plotting the crossover points (Ct) against the log
(SNU-16 cell number). Relative DDC mRNA values in patient samples
were calculated with reference to this curve.
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Figure 2 Specificity of DDC expression. (A) DDC mRNA expressions
in various gastric cancer cell lines were analysed by Northern blotting.
Northern blot analysis of differently expressed genes in eight gastric cancer
cells. Upregulated genes in gastric cancer cells from malignant ascites
compared to those in the primary lesion. (B) DDC mRNA expression in
primary gastric cancers, normal gastric mucosa and mesothelial cells were
analysed by quantitative RT–PCR. Well: well-differentiated adenocarcino-
noma; poor: poorly differentiated adenocarcinoma.
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DDC mRNA/b-actin mRNA ( 10
7) is shown in Figure 3. The DDC
mRNA/b-actin mRNA ratio was significantly higher for cases
positive for invasiveness of the serosa than for negative cases.
DDC as an independent prognostic factor
The highest value of the DDC mRNA/b-actin mRNA ratio
determined for noncancer cases undergoing gastric surgery was
adopted as the cutoff value (broken line on the graph), and values
greater than this value were regarded as positive (DDCþ). Of the
total of 112 cases, 20 were determined to be DDC positive, and 15
showed positive cytology (CYþ) or were observed to have
peritoneal metastases. Since 13 of these 15 subjects had results
above the cutoff value, they were classified as DDCþ (86%
sensitivity). Moreover, one of the 48 t1 cases was DDCþ (98%
specificity) (Figure 4).
Comparison of sensitivity and specificity of DDC and CEA
as markers for peritoneal micrometastasis of gastric cancer
CEA mRNA/b-actin mRNA was also measured in all clinical
samples, and the results are presented as the CEA mRNA/b-actin
mRNA ratio. The results for CEA mRNA/b-actin mRNA ( 1000)
were: t1, 5.3þ3.5; t2, 8.4þ6.8; t3, 71.1þ22.8; and t4, 643.9þ
378.3. A correlation was observed between the degree of wall
invasion and the level of CEA mRNA/b-actin mRNA (data not
shown). Moreover, when classified, according to the invasion of
serosa into positive (t3, t4) and negative (t1, t2), a significant
difference was observed between the two groups (data not shown).
The highest value for the CEA mRNA/b-actin mRNA ratio in
noncancer cases was set as the cutoff value, and the cases showing
a value greater than this were regarded as CEA positive. Of the 15
subjects who were also CYþ or were intraoperatively observed to
have peritoneal metastasis, 11 were CEAþ. However, for four
subjects below the cutoff value, (CEA ) metastasis was observed
(73% sensitivity), and three of the 48 subjects who were t1 cases
were classified as CEAþ (93% specificity) (Tables 2 and 3).
Although four subjects (cases 2, 11, 14 and 15 in Table 3)
registered a CEA – a result of poorly differentiated adenocarcino-
ma, they showed evidence of peritoneal metastasis at an early
stage. Three of these cases showed positive DDC mRNA/b-actin
mRNA ratio results (Tables 2 and 3). As shown in Figure 2, DDC is
frequently overexpressed in poorly differentiated adenocarcino-
mas, suggesting that DDC is viable as a novel marker for cases that
Table 1 Summary of DDC mRNA and clinicopathological factors in gastric cancer patients
DDC mRNA
Variables Positive Negative P-value*
Sex Male 9 44 NS
Female 11 48 (0.7332376)
Differentiation Differentiated 4 47 0.002314**
Undifferentiated 16 45
Depth of invasion t1, t2 3 66 0.0073323**
t3, t4 17 26
Lymphatic invasion Negative 3 45 0.0322323**
Positive 17 47
Vascular invasion Negative 11 48 N.S.
Positive 9 44 (0.067332376)
Lymph node metastasis Negative 3 42 0.037622**
Positive 17 50
Peritoneal dissemination Negative 2 90 0.0013339**
Positive 18 2
t = classification: t1¼mucosa to submucosa; t2¼muscularis propria to subserosa; t3¼serosa-exposed; t4¼serosa-infiltrating. *Mann–Whitney test; **statistically significant,
NS¼not significant.
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Figure 3 Relative values for DCC mRNA/b-actin mRNA ratios in
peritoneal washes of gastric carcinoma patients by depth of invasion (pT
category). DDC mRNA values correlated with depth of cancer invasion
(Po0.01).
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Douglas cavity measured by real-time RT–PCR with the Light Cycler in
gastric cancer patients with or without synchronous peritoneal metastasis.
DDC mRNA values for washes from metastasis-positive patients were
significantly higher than those for metastasis-negative patients (Po0.001).
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of CEA and DDC improved the accuracy of diagnosis up to 94%.
DISCUSSION
Peritoneal dissemination is the most frequent pattern of gastric
cancer recurrence and prognosis for gastric cancer patients with
peritoneal dissemination is invariably poor. Some previous reports
have indicated that intraperitoneal chemotherapy improves the
survival of these patients, but it can sometimes be life-threatening
because of side effects. We developed a novel technique to
administer the anticancer agent mitomycin-C adsorbed on
activated carbon particles (MMC-CH) (Hagiwara et al, 1992,
1993a,b, 1999; Takahashi et al, 1995). This form of administration
can deliver a large amount of the anticancer agent, because the
corpuscular particles are not absorbed through the capillary wall.
Instead, they are retained in the cavity, which remains closed for a
long time and thus can maintain a high concentration of
anticancer agents. We previously reported on this new form of
drug administration and its therapeutic efficacy for peritonitis
carcinomatosa of gastric cancers (Hagiwara et al, 1992). However,
sometimes side effects occur such as ileus, fever, leukocytopenia
and so on, so that it has been necessary to determine the indication
for this therapeutic application to avoid such side effects.
The extreme sensitivity of RT–PCR makes it possible to
diagnose micrometastases on the basis of tissue-specific mRNA
expression of tumour cells in peripheral blood, bone marrow,
lymph nodes and cerebrospinal fluid (Burchill et al, 1995; Johnson
et al, 1995; Maehara et al, 1996; Noguchi et al, 1996; Mori et al,
1998). Recently, the use of rapid quantitative RT–PCR-based
screening methods for the detection of micrometastasis from
clinical specimens has become standard procedure (Nakanishi
et al, 2000; Sato et al, 2001; Oki et al, 2002). Many different kinds
of molecular markers for the detection of peritoneal micrometas-
tases have been described, such as conventional RT–PCR assay of
CEA, keratin 19 and AFP using the peritoneal wash from gastric
cancers (Nakanishi et al, 1997; Schmidt et al, 2001). Other reports
have dealt with novel markers for the detection of micrometas-
tases. Yonemura et al (2001) increased the sensitivity of detection
to 62% by using a combination of CY and RT–PCR of MMP-7
mRNA. Schuhmacher et al (1999) used RT–PCR to show the
relationship between the expression of E-cadherin mutation and
metastasis to the peritoneum. But any assay using peritoneal wash
is inferior in sensitivity and specificity when compared to the
Table 3 Clinicopathological features of cases with peritoneal recurrence of gastric cancer and quantitative results of DDC and CEA for peritoneal washes
Markers
Case no. Stage
a Histology
b CEA DDC CEA and DDC
1 P1H0N2T3CY1 Stage IV por + + +
2 P0H0N2T3CY0 Stage IIIB sig   ++
3 P0H0N1T3CY1 Stage IV por + + +
4 P0H0N1T3CY0 Stage IIIA tub + + +
5 P1H0N2T3CY0 Stage IIIB sig + + +
6 P0H1N1T4CY1 Stage IV sig + + +
7 P0H1N3T3CY0 Stage IV por + + +
8 P1H1N2T3CY0 Stage IV por + + +
9 P0H0N2T3CY1 Stage IV sig + + +
10 P1H0N1T4CY1 Stage IV por     
11 P0H0N2T3CY0 Stage IIIB muc + + +
12 P0H0N3T3CY0 Stage IV pap + + +
13 P0H0N1T3CY0 Stage IIIA sig + + +
14 P0H0N2T3CY1 Stage IV por   ++
15 P0H0N2T3CY1 Stage IV por   ++
Sensitivity for the detection of MM 73% (11/15) 87% (13/15) 94% (14/15)
These cases were subsequently found to show recurrence of peritoneal carcinomatosa.
aClinical stage according to Japanese Gastric Cancer Classification.
bHistology of the
primary lesion according to Japanese Gastric Cancer Classification.por¼poorly differentiated adenocarcinoma, sig¼signet ring cell carcinoma, tub¼tubular adenocarcinoma,
muc¼mucinous carcinoma, pap¼papillary adenocarcinoma.
Table 2 Summary of –RTPCR results for DDC/CEA expression and peritoneal wash in gastric cancer
No. of positive cases in quantitative RT–PCR
Depth of invasion No. of patients CEA DDC Cytology
Primary tumour
t1 48 3 (3%) 1 (2%) 0 (0%)
t2 21 2 (9%) 2 (9%) 0 (0%)
t3 29 9 (31%) 10 (34%) 5 (17%)
t4 14 5 (36%) 7 (50%) 2 (15%)
Total 112 19 (16%) 20 (18%) 14 (20%)
Benign disease 15 0 (0%) 0 (0%) 0 (0%)
t classification: t1¼mucosa to submucosa; t2¼muscularis propria to subserosa; t3¼serosa-exposed; t4¼serosa-infiltrating.
DDC for gastric cancer peritoneal micrometastasis
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CEA is recently a standard molecular marker for the detection of
gastric cancer micrometastasis. However, it is not expressed in all
cases of peritoneal metastases, and very weakly in mesothelial cells,
so that it is difficult to exclude false-positive or false-negative
cases. This means that markers with greater sensitivity and
specificity are needed to reduce misdiagnosis. It is very important
to choose specifically expressed genes, which are most useful as
markers of peritoneal dissemination, in order to exclude false-
positive or false-negative readings. In other words, genes with a
much higher expression in cancer cells than in mesothelial cells
should be chosen. One of the novel markers selected by DNA
microarray is DDC, which satisfies the above conditions.
DDC is responsible for the synthesis of the key neurotransmit-
ters dopamine and serotonin, and is frequently expressed in
neuroblastoma and small-cell carcinoma of the lung (North and
Du, 1998; Gilbert et al, 1999). It is used for the differential
diagnosis of neuroblastoma from other paediatric small round cell
malignancies (Gilbert et al, 2000). DDC expression is also
considered to be a marker for neuroendocrine differentiation in
lung cancer cell lines (Jensen et al, 1990). Finally, it is also known
as L-amino acid decarboxylase, which catalyses the synthesis of
biogenic amines involved in different important functions, such as
angiogenesis, cell proliferation, apoptosis and cell proliferation
(Berry et al, 1996; Medina et al, 1999), which suggests that it plays
an important role in gastric cancer progression.
In conclusion, our results show that DDC-specific RT–PCR is
more sensitive than conventional CY or CEA–RT–PCR of
peritoneal wash, so that this method may well be useful for the
prediction of peritoneal recurrence in gastric cancer patients. In
view of the correlation established by our study between PCR
results and cancer recurrence, the use of DDC RT–PCR to predict
peritoneal recurrence of gastric cancer is likely to be effective. A
large-scale, long-term follow-up study is currently underway in our
department to ascertain the actual rate of peritoneal recurrence in
CY  and PCR-positive patients and to determine whether negative
patients in fact remain disease-free. DDC is overexpressed in
gastric cancer peritoneal dissemination, but the role of DDC in
such dissemination is still unclear, so that further investigation is
necessary to clarify it.
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